Abstract
Cancer is fundamentally a genomic disease caused by mutations or rearrangements in the DNA or epigenetic machinery of a patient. An emerging field in cancer treatment targets key aberrations arising from the mutational landscape of an individual patient’s disease rather than employing a cancer-wide cytotoxic therapy approach. In prostate cancer in particular, where there is an observed variation in response to standard treatments between patients with disease of a similar pathological stage and grade, mutationdirected treatment may grow to be a viable tool for clinicians to tailor more effective treatments. This review will describe a number of mutations across multiple forms of cancer that have been successfully antagonised by targeted therapeutics including their identification, the development of targeted compounds to combat them and the development of resistance to these therapies. This review will continue to examine these same mutations in the treatment and management of prostate cancer; the prevalence of targetable mutations in prostate cancer, recent clinical trials of targeted-agents and the potential or limitations for their use.
Keywords: Precision medicine, prostate cancer, targeted therapeutics.
Current Cancer Drug Targets
Title:Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer
Volume: 15 Issue: 5
Author(s): Ryan Stuchbery, Natalie J. Kurganovs, Patrick J. McCoy, Colleen C. Nelson, Vanessa M. Hayes, Niall M. Corcoran and Christopher M. Hovens
Affiliation:
Keywords: Precision medicine, prostate cancer, targeted therapeutics.
Abstract: Cancer is fundamentally a genomic disease caused by mutations or rearrangements in the DNA or epigenetic machinery of a patient. An emerging field in cancer treatment targets key aberrations arising from the mutational landscape of an individual patient’s disease rather than employing a cancer-wide cytotoxic therapy approach. In prostate cancer in particular, where there is an observed variation in response to standard treatments between patients with disease of a similar pathological stage and grade, mutationdirected treatment may grow to be a viable tool for clinicians to tailor more effective treatments. This review will describe a number of mutations across multiple forms of cancer that have been successfully antagonised by targeted therapeutics including their identification, the development of targeted compounds to combat them and the development of resistance to these therapies. This review will continue to examine these same mutations in the treatment and management of prostate cancer; the prevalence of targetable mutations in prostate cancer, recent clinical trials of targeted-agents and the potential or limitations for their use.
Export Options
About this article
Cite this article as:
Stuchbery Ryan, Kurganovs J. Natalie, McCoy J. Patrick, Nelson C. Colleen, Hayes M. Vanessa, Corcoran M. Niall and Hovens M. Christopher, Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer, Current Cancer Drug Targets 2015; 15 (5) . https://dx.doi.org/10.2174/1568009615666150416113453
DOI https://dx.doi.org/10.2174/1568009615666150416113453 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Aspects of FKBP51 that Enable Melanoma Dissemination
Current Molecular Pharmacology Targeting the p53-Family in Cancer and Chemosensitivity: Triple Threat
Current Drug Targets Bioinformatics Approaches to Profile the Tumor Microenvironment for Immunotherapeutic Discovery
Current Pharmaceutical Design Human Reduced Folate Carrier Gene and Transcript Variants: Functional, Physiologic, and Pharmacologic Consequences
Current Pharmacogenomics Exploring Pharmacological Significance of Chalcone Scaffold: A Review
Current Medicinal Chemistry Meet Our Editorial Board Member
Current Signal Transduction Therapy Defining Statistical Race and Phenotypic Race and Their Implications for Health Disparities
Current Pharmacogenomics and Personalized Medicine NF-κB Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization
Current Pharmaceutical Design Progesterone Receptor Agonists and Antagonists as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Military Risk Factors for Cognitive Decline, Dementia and Alzheimer’s Disease
Current Alzheimer Research Licochalcone B Arrests Cell Cycle Progression and Induces Apoptosis in Human Breast Cancer MCF-7 Cells
Recent Patents on Anti-Cancer Drug Discovery High Dose Immunoglobulin (IVIG) May Reduce the Incidence of Langerhans Cell Histiocytosis (LCH)-Associated Central Nervous System Involvement
CNS & Neurological Disorders - Drug Targets The Important Roles of miR-205 in Normal Physiology, Cancers and as a Potential Therapeutic Target
Current Cancer Drug Targets Pharmacokinetics of Darolutamide, its Diastereomers and Active Metabolite in the Mouse: Response to Saini NK et al. (2020)
Drug Metabolism Letters Pharmacokinetic and Toxicological Characteristics of Tripterigium Glycosides and Their Derivatives
Current Drug Metabolism Editorial [Hot topic: Apoptosis in Carcinogenesis and Cancer Therapy (Guest Editors: George G. Chen and Paul B.S. Lai)]
Current Cancer Drug Targets Anticipation in Lynch Syndrome: Where We Are Where We Go
Current Genomics Carotenoids as Modulators of Intracellular Signaling Pathways
Current Signal Transduction Therapy New Insights in Drug-Induced Mitochondrial Toxicity
Current Pharmaceutical Design Delivery of Therapeutics and Molecules Using Self-Assembled Peptides
Current Medicinal Chemistry